Microgynon®
Sponsors
Hoffmann-La Roche, Boehringer Ingelheim, Novo Nordisk A/S, Merck KGaA, Darmstadt, Germany
Conditions
DiabetesDiabetes Mellitus, Type 2HealthyHealthy VolunteerRelapsing Multiple Sclerosis (RMS)
Phase 1
A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers
CompletedNCT01615354
Start: 2012-07-31End: 2013-01-31Updated: 2016-11-02
Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel
TerminatedNCT01941615
Start: 2013-11-30End: 2014-01-31Updated: 2016-04-11
Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects
CompletedNCT02175394
Start: 2008-07-31Updated: 2014-07-08
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females
CompletedNCT02845219
Start: 2016-07-31End: 2016-12-31Updated: 2017-06-07
Effects of Cladribine Tablets on the PK of Microgynon®
CompletedNCT03745144
Start: 2019-01-17End: 2022-09-16Updated: 2024-03-15
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
CompletedNCT05153564
Start: 2021-12-13End: 2022-09-01Updated: 2023-11-13
A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood
CompletedNCT05613777
Start: 2022-11-24End: 2023-10-04Updated: 2023-10-19
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
CompletedNCT05896384
Start: 2023-12-21End: 2025-03-26Updated: 2025-04-16